Clinical trials: Myocardial Perfusion Imaging
Coronary Artery Disease (CAD)
An International Study to Evaluate Diagnostic Efficacy of Flurpiridaz (18F) Injection PET MPI in the Detection of Coronary Artery Disease (CAD)
This is a Phase 3, prospective, open-label, international, multicentre study of Flurpiridaz (18F) Injection for PET MPI in patients referred for ICA because of suspected CAD.
- Trial name
- NCT03354273
- Testing
- PET MPI, SPECT MPI, Pharmacological stress agents
- Where
- 53 sites in United States, Canada and 5 more
- Volunteers
- 730 people
- Sponsor
- GE Healthcare
Coronary Artery Disease
Phase 3 Imaging and Safety Study of AI-700 in Patients With Suspected Coronary Artery Disease Undergoing SPECT Imaging
This study was designed to evaluate the ability of AI-700-enhanced rest-stress echocardiography to detect coronary artery disease (CAD) in patients with suspected ischemic heart disease who are indicated for single-photon…
- Trial name
- NCT00156793
- Testing
- AI-700 contrast-enhanced echocardiography
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Acusphere
Coronary Artery Disease (CAD)
A Long-term Follow-up Study to Evaluate the Predictive Value of BMS747158 in Patients Suspected of Coronary Artery Disease (CAD)
This long-term study will follow patients with known or suspected of having coronary artery disease (CAD) and have participated in present and future BMS747158 clinical studies.
- Trial name
- NCT01085162
- Testing
- BMS747158
- Where
- United States
- Sponsor
- Lantheus Medical Imaging
Coronary Artery Disease
RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW)
This a Phase 3, prospective, open-label, multicenter study of [15-O]-H2O injection for PET imaging of subjects with suspected CAD.
- Trial name
- NCT05134012
- Testing
- [O-15]-Water PET Myocardial Perfusion Imaging (MPI)
- Where
- 13 sites in United States, Canada and 4 more
- Volunteers
- 215 people
- Sponsor
- MedTrace Pharma A/S
Coronary Artery Disease
Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI
The purpose of this study is to see whether apadenoson is as effective as adenosine when used as a pharmacological stress agent in myocardial SPECT-imaging (SPECT-MPI)to detect defects in the supply of blood to the heart muscle…
- Trial name
- ASPECT2 (NCT01313572)
- Testing
- Apadenoson SPECT-MPI, Adenosine SPECT-MPI
- Where
- 86 sites in United States, Argentina and 3 more
- Volunteers
- 197 people
- Sponsor
- Forest Laboratories
Coronary Artery Disease
A Phase I Study of a Novel Tracer for Positron Emission Tomography "PET" Myocardial Perfusion Imaging "MPI"
[11C]-dimethyl-diphenyl ammonium ([11C]-DMDPA) - A Phase I, Open-label, Safety and Tolerability, Radiation Dosimetry, Biodistribution, First-in-Human Study of a Novel 11C-labeled Tracer for Positron Emission Tomography Myocardial…
- Trial name
- NCT02720354
- Testing
- [11C]-DMDPA
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Synektik S.A.
Coronary Artery Disease
A Phase I Study to Evaluate BFPET as a Potential Myocardial Perfusion Imaging(MPI) Agent for PET
Safety and dosimetry of BFPET™ will be evaluated in healthy volunteers and Coronary Artery Disease (CAD) patients , male or female and of age ranging between 20-80 years old.
- Trial name
- NCT00733460
- Testing
- BFPET
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Fluoropharma, Inc.
Coronary Artery Disease
Direct Comparison of 2D Cardiac PET With 3D Cardiac PET
Lowering the per-infusion dose of Rb-82 offers advantages of lessening radiation exposure and extending useable generator life. Prior studies have not shown equivalence of 3D vs 2D Rb-82 PET.
- Trial name
- NCT01993303
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Cardiovascular Imaging Technologies
Coronary Artery Disease
ADVANCE MPI 2: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)
Adenoscan® (adenosine) is an approved pharmacological stress agent indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately.
- Trial name
- NCT00208312
- Testing
- Regadenoson, Adenosine
- Where
- United States
- Volunteers
- 787 people
- Sponsor
- Gilead Sciences
Coronary Artery Disease
ADVANCE MPI 1: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)
Adenoscan® (adenosine) is an approved pharmacological stress agent indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately.
- Trial name
- NCT00208299
- Testing
- Regadenoson, Adenosine
- Where
- United States
- Volunteers
- 1,231 people
- Sponsor
- Gilead Sciences
Coronary Artery Disease, Healthy
Evaluation and Optimization of PB127 Myocardial Perfusion Echocardiography on Ultrasound Systems
The purpose of this clinical trial is to evaluate various commercially available ultrasound systems and to identify imaging parameters to be used with these systems (along with the contrast agent PB127) as well as to further…
- Trial name
- NCT00487903
- Testing
- PB127 for Injectable Suspension
- Where
- 3 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Point Biomedical
Coronary Artery Disease (CAD)
A Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging (MPI) Using Multidetector Computed Tomography (MDCT) Compared to Single Photon Emission Computed Tomography (SPECT)
The purpose of this study is to compare Multidetector Computed Tomography (MDCT) and Single Photon Emission Computed Tomography (SPECT) stress myocardial perfusion imaging (MPI) with regadenoson in order to detect the presence or…
- Trial name
- NCT01334918
- Testing
- regadenoson, technetium Tc99m sestamibi /technetium Tc99m tetrafosmin, Contrast
- Where
- 11 sites in United States
- Volunteers
- 124 people
- Sponsor
- Astellas Pharma Inc
Cardiovascular Disease, Ischemic Heart Disease
A Phase II Optimization Study of BMS068645 and Sestamibi Planar Imaging
The primary purpose of this study is to determine the optimal time for myocardial perfusion imaging with Technetium Tc99m Sestamibi following the administration of BMS068645. The safety of BMS068645 will also be studied.
- Trial name
- NCT00162071
- Testing
- apadenoson
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Forest Laboratories
Coronary Artery Disease
Efficacy and Safety Study of Binodenoson in Assessing Cardiac Ischemia
Binodenoson (an experimental drug) and adenosine (an FDA-approved drug that is currently used by doctors) are used to increase blood flow to the heart just like when a person exercises on a treadmill.
- Trial name
- VISION-305 (NCT00944970)
- Testing
- binodenoson, adenosine
- Volunteers
- 578 people
- Sponsor
- Pfizer
Coronary Artery Disease (CAD)
Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)
Observe whether the administration of caffeine prior to regadenoson will affect the interpretation of test results in subjects with coronary artery disease (CAD) undergoing SPECT MPI
- Trial name
- NCT00826280
- Testing
- regadenoson, overencapsulated caffeine, technetium
- Where
- 25 sites in United States
- Volunteers
- 347 people
- Sponsor
- Astellas Pharma Inc
Coronary Artery Disease
A Comparison Study of Apadenoson and Adenosine to Treadmill Exercise Stress.
The purpose of this clinical research study is to compare Apadenoson and adenosine to treadmill exercise stress SPECT MPI
- Trial name
- NCT00380198
- Testing
- Apadenoson
- Where
- 42 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- Forest Laboratories
Myocardial Perfusion Imaging, Magnetic Resonance Imaging
Myocardial Perfusion MRI
The object of this study is to compare four different dosages of Gadavist 1.0 in cardiac Magnetic Resonance Tomography (MRT) imaging with the imaging results of a cardiac SPECT examination in terms of diagnostic quality.
- Trial name
- NCT01490294
- Testing
- Gadobutrol (Gadavist,Gadovist, BAY86-4875)
- Where
- 14 sites in Austria, Germany and 2 more
- Volunteers
- 232 people
- Sponsor
- Bayer
Coronary Artery Disease
Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI
The purpose of this study is to see whether apadenoson is as effective as adenosine when used as a pharmacological stress agent in myocardial SPECT-Imaging to detect defects in the supply of blood to the heart muscle (myocardial…
- Trial name
- ASPECT (NCT00990327)
- Testing
- Apadenoson SPECT-MPI, Adenosine SPECT-MPI
- Where
- 122 sites in United States, Brazil
- Volunteers
- 863 people
- Sponsor
- Forest Laboratories
Coronary Artery Disease
A Study of Gadodiamide Injection in Myocardial Perfusion Magnetic Resonance Imaging
The purpose of this study is to determine how well perfusion cardiac magnetic resonance (MR) imaging is able to detect certain heart abnormalities, such as a coronary artery narrowing.
- Trial name
- MR-IMPACT-II (NCT00977093)
- Testing
- Perfusion CMR for detection of coronary artery disease, Perfusion cardiac magnetic resonance imaging
- Volunteers
- 533 people
- Sponsor
- Amersham Buchler, GmbH & Co KG
Coronary Artery Disease
Gadobutrol / Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)
Subjects being evaluated for suspected or known Coronary artery Disease (CAD) based on signs and/or symptoms, will be invited to participate in the study.
- Trial name
- GadaCAD 2 (NCT01890434)
- Testing
- Gadobutrol (Gadavist, Gadovist, BAY86-4875)
- Where
- 24 sites in United States, Australia and 2 more
- Volunteers
- 478 people
- Sponsor
- Bayer